Market Cap : 134.85 B | Enterprise Value : 162.19 B | PE Ratio : 21.37 | PB Ratio : 55.75 |
---|
NAS:AMGN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:AMGN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Amgen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $817 Mil. Amgen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $35,705 Mil. Amgen's annualized EBITDA for the quarter that ended in Jun. 2022 was $10,748 Mil. Amgen's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 was 3.40.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for Amgen's Debt-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest Debt-to-EBITDA Ratio of Amgen was 4.24. The lowest was 2.37. And the median was 2.79.
AMGN's Debt-to-EBITDA is ranked worse thanThe historical data trend for Amgen's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Amgen's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Amgen's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Amgen's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Amgen's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (87 | + | 33222) | / | 11296 | |
= | 2.95 |
Amgen's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (817 | + | 35705) | / | 10748 | |
= | 3.40 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2022) EBITDA data.
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of Amgen's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Miller Derek | officer: SVP, Human Resources | ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
Khosla Rachna | officer: SVP, Business Development | ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
Ishrak Omar | director | 710 MEDTRONIC PKWY MS LC300 MINNEAPOLIS MN 55432 |
Louie Linda H. | officer: VP, Finance & CAO | ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
Miles Amy E | director | |
Grygiel Nancy A. | officer: SVP & CCO | ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
Griffith Peter H. | officer: EVP & CFO | ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
Gordon Murdo | officer: EVP Global Commercial Ops | C/O BRISTOL-MYERS SQUIBB COMPANY 345 PARK AVE NEW YORK NY 10154 |
Reese David M | officer: EVP, Research and Development | ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
Druker Brian | director | ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799 |
Austin Wanda M | director | 6001 BOLLINGER CANYON ROAD SAN RAMON CA 94583 |
Holley Charles M | director | |
Johnston Lori A | officer: SVP, HR | C/O AMGEN INC. ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
Kullman Ellen Jamison | director | UNITED TECHNOLOGIES CORP 10 FARM SPRINGS ROAD FARMINGTON CT 06032 |
Santos Esteban | officer: EVP, Operations | ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 |
From GuruFocus
By PRNewswire 02-16-2022
Other Sources
By Zacks 2022-04-04
By Zacks 2022-03-28
By Zacks 2022-03-22
By Fool 2022-04-01
By Zacks 2022-03-08
By tipranks.com 2022-03-03
By Zacks 2022-02-25
By Zacks 2022-04-05
By Zacks 2022-03-24
By Zacks 2022-03-21
By Zacks 2022-03-15
By Zacks 2022-03-24
By tipranks.com 2022-03-22
By tipranks.com 2022-02-28